Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis
Corcept Therapeutics is piecing together a path forward for an experimental drug that failed a mid-stage ALS study after new data showed the treatment boosted survival outcomes. Back in December, the selective cortisol modulator, called ...
Corcept Therapeutics is piecing together a path forward for an experimental drug that failed a mid-stage ALS study after new data showed the treatment boosted survival outcomes.
Back in December, the selective cortisol modulator, called ...
